scholarly journals Complete Response Induced by Concurrent Chemoradiotherapy in a Patient with NUT Carcinoma: A Case Report

2022 ◽  
Author(s):  
Joji Muramatsu ◽  
Kohichi Takada ◽  
Shintaro Sugita ◽  
Takaaki Tsuchiya ◽  
Keisuke Yamamoto ◽  
...  
Keyword(s):  
Case Report ◽  
Concurrent Chemoradiotherapy ◽  
Complete Response ◽  
Nut Carcinoma

scholarly journals Complete response induced by concurrent chemoradiotherapy in a patient with NUT carcinoma: a case report

2021 ◽  
Author(s):  
Joji Muramatsu ◽  
Kohichi Takada ◽  
Shintaro Sugita ◽  
Takaaki Tsuchiya ◽  
Keisuke Yamamoto ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Concurrent Chemoradiotherapy ◽  
Vision Loss ◽  
Locally Advanced ◽  
Complete Response ◽  
Adolescent And Young Adult ◽  
Pathological Examination ◽  
Positive Staining ◽  
Dismal Prognosis ◽  
Nut Carcinoma

Abstract BackgroundNUT carcinoma (NC) is a rare and extremely aggressive carcinoma that occurs in young individuals. Although NC has a dismal prognosis, recommended therapies have not been established.Case presentationAn 18-year-old man presented with sudden vision loss in his left eye. Magnetic resonance imaging revealed a rapidly growing tumor, which had directly invaded the left optic nerve and epidural space, originating from the left posterior ethmoid sinus. A pathological examination of the tumor revealed a dense proliferation of polygonal-to-round tumor cells with enlarged round nuclei and conspicuous nucleoli, and positive staining for NUT protein in the nuclei of tumor cells. The patient was diagnosed with locally advanced NC. We initiated concurrent chemoradiotherapy (CCRT), consisting of chemotherapy with vincristine, doxorubicin, and cyclophosphamide (VDC), alternating with ifosphamide and etoposide (IE) according to a regimen for Ewing sarcoma, plus radiation therapy (70 Gy/35 Fr). The patient completed CCRT and achieved a complete response.ConclusionsCCRT, comprising a VDC–IE regimen, can be a useful treatment option for adolescent and young adult patients with NC, even when the cancer is at a locally advanced unresectable stage.

Duvelisib as bridge to allotransplantation in refractory peripheral T-cell lymphoma with T-follicular helper phenotype: case report

2021 ◽  
pp. 030089162110272
Author(s):  
Ginevra Lolli ◽  
Beatrice Casadei ◽  
Cinzia Pellegrini ◽  
Lisa Argnani ◽  
Federica Cocito ◽  
...  
Keyword(s):  
Case Report ◽  
T Cell ◽  
Human Leukocyte ◽  
Complete Response ◽  
Unrelated Donor ◽  
Phosphatidylinositol 3 Kinase ◽  
Leukocyte Antigen ◽  
Follicular Helper ◽  
T Cell Lymphomas ◽  
T Cell Malignancies

Objective: Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous T-cell malignancies representing 5%–10% of aggressive lymphomas. The prognosis is poor for patients with relapsed/refractory (R/R) disease, with a median overall survival of less than 6 months and no standardized treatments. We discuss the role of the phosphatidylinositol 3-kinase (PI3K) γδ inhibitor duvelisib as bridge to allotransplantation in a patient with R/R PTCL. Methods: Case report. Results: A 55-year-old woman diagnosed with relapsed nodal PTCL with T-follicular helper phenotype received PI3K γδ inhibitor duvelisib in the context of the phase II PRIMO clinical trial. After two cycles at a dose of 75 mg twice daily, the patient achieved complete response (CR), which was subsequently consolidated with human leukocyte antigen fully matched unrelated donor allotransplantation. No major toxicities were recorded during the duvelisib treatment period or during hospitalization for allotransplantation. At the latest follow-up, the patient was alive and still in CR 10 months posttransplant. Conclusions: Duvelisib should be further explored as a bridge to allotransplantation in patients with R/R PTCL, given the success and low toxicity in our patient.

Re-use of erlotinib in a patient using osimertinib after erlotinib, case report

2021 ◽  
pp. 107815522110191
Author(s):  
Pinar Gursoy
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Treatment Options ◽  
Resistance Mutation ◽  
Growth Factor Receptor ◽  
Complete Response ◽  
Egfr Mutations ◽  
T790m Mutation ◽  
Development Of Resistance ◽  
Exon 19

Introduction Most patients with non-small-cell lung cancer tumors that have epidermal growth factor receptor (EGFR) mutations have deletion mutations in exon 19 or exon 21, or both.In recent years, targeted therapies in lung cancer have increased survival, but the development of resistance to these drugs poses a major problem. Thesubstitution of methionineforthreonine at position 790 (T790M) mutation,is primarily responsible for this resistance. However, after osimertinib used in T790M positivepatients treatment options are generally limited to chemotherapy. Case report We reported the efficacy of erlotinib, which we reapplied due to the disappearance of the resistance mutation after osimertinib in a 68-year-old patient using osimertinib after erlotinib. Management and outcome: In the patient using erlotinib due to exon 19 deletion when progression was observed and T790M positivity was detected, osimertinib treatment was initiated. However, when T790M was found to be negative with rebiopsy in progression after osimertinib, a complete response was achieved by restarting erlotinib. Discussion The strategy of restarting erlotinib treatment with negative T790M mutation detected in biopsies of patients with osimertinib resistance may be an acceptable treatment option.

scholarly journals Changing the Prognosis of Metastatic Cervix Uteri Adenosquamous Carcinoma through a Multimodal Approach: A Case Report

2020 ◽  
Vol 13 (3) ◽  
pp. 1545-1551
Author(s):  
Mihai Teodor Georgescu ◽  
Dragos Eugen Georgescu ◽  
Teodor Florin Georgescu ◽  
Luiza Georgia Serbanescu
Keyword(s):  
Case Report ◽  
Adenosquamous Carcinoma ◽  
Treatment Approach ◽  
Complete Response ◽  
Team Work ◽  
Cervix Uteri ◽  
Multimodal Approach ◽  
Rare Cancer ◽  
Management Guidelines ◽  
Cancer Subtypes

Adenocarcinoma and adenosquamous carcinoma (AS) are 2 rare histological types of cervix uteri cancer constituting almost 20% of all cervix cancers, leading to a lack in patient management guidelines. We report the case of a 32-year-old woman with an oligometastatic cervix AS for which a multimodal treatment approach was used. Despite the patient’s bad prognosis, a complete response was achieved, which further resulted in excellent local control and prolonged survival. This case report serves the purpose of encouraging multidisciplinary team work and out-of-the-box thinking that should result in an individualized treatment for rare cancer subtypes.

Sign in / Sign up

Export Citation Format

Share Document